2Vajo Z, Duckwonh WC. Genetically engineered insulin analogs:diabetes in the new millennium. Pharmacol Rev 2000,52(1):1-9.
3Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus, Ann Pharmacother 1996, 30(11) : 1263-1271.
4Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment, Diabetes 1997, 46:265- 270.
5White JR, Campbell RK. Recent developmenls in the Pharmacological reduction of blood glucose in patients with type 2 diabetes. Clinical Diadetes 2001,19:153-159.
6Roach P, Trautmann M, Arora V, et al, Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro - protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Mix50 Study Group. Clin Ther 1999,21(3):523-534.
7Jacobsen LV, Sogaard B, Riis A. Pharmaacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine - retarded insulin aspart. Eur J Clin Pharmacol 2000.56(5) :399-403.
8Ratner RE, Hirsch IB, NeifingJL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type Ⅰ diabetes, U, S, Study Group of Insulin Glargine in Type 1 Diabetes, Diabetes Care 2000, 23(5) : 639- 643.
9Yki - Jarvinen H, Dressier A, Ziemen M, et al. Less nocturnal hypoglycemia and batter post - dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23(8) : 1130-1136.
10Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analog insulin detemir with NPH Insulin. Diabetes Care 2001, 24:296-301.
